

ASX ANNOUNCEMENT

20 October 2016

### ARGOSY RAISES \$3M TO FAST-TRACK RINCON LITHIUM

Placement to cornerstone strategic investors at 3 cents per share

#### HIGHLIGHTS

- Argosy has issued 100 million shares at an issue price of 3 cents per share to sophisticated and professional investors at a significant premium to the last traded share price.
- → Funds to be used to progress pilot plant development at the Rincon Lithium Project.

Argosy Minerals Limited (ASX: AGY) ("Argosy" or the "Company") is pleased to announce it has completed a share placement to a group of strategic investors to raise \$3,000,000 ("Placement"). 100 million new shares have been issued at a price of 3 cents per share, representing a significant premium to the last traded price of the Company's securities.

The cornerstone strategic investors have expressed support and longer-term commitment to the Company, our Rincon Lithium Project development plan, and ultimately, to target commercial production from the Project.

Commenting on the Placement, Argosy Director, Jerko Zuvela, said "This is a clear endorsement of our development strategy and quality of the Rincon Lithium Project. Funds from the placement will be primarily used to progress the stage 1 pilot plant at Rincon, with the aim to demonstrate Argosy's potential to produce a saleable clean lithium carbonate equivalent product ahead of much of the peer group."

#### **PLACEMENT DETAILS**

Under the Placement, the Company has issued a total of 100,000,000 new shares to sophisticated and professional investors using the placement capacity available under ASX Listing Rule 7.1 and 7.1A. The new shares have been issued on the same terms as, and will rank equally in all respects with, the existing fully paid ordinary shares in the Company.

#### USE OF FUNDS

The Placement proceeds will be used primarily to advance the first stage of the Rincon Lithium Project development plan – to produce a laboratory scale quantity of lithium carbonate equivalent (LCE) product. The Company will also use the funds to progress its other projects and for general working capital requirements.

Also attached to this announcement is the Company's Appendix 3B and the necessary additional disclosures required under Listing Rule 3.10.5A.



Page 1 of 2



#### ASX ANNOUNCEMENT

For more information on Argosy Minerals Limited and to subscribe for regular updates, please visit our website at: <u>www.argosyminerals.com.au</u> or contact us via <u>admin@argosyminerals.com.au</u>.

ENDS

#### For further information:

Jerko Zuvela Director

**T** | +61 8 9226 4500

E | admin@argosyminerals.com.au

W www.argosyminerals.com.au

#### ABOUT ARGOSY MINERALS LIMITED

Argosy Minerals Limited (ASX: AGY) is an Australian company with interests in the Rincon, Mina Teresa and Pocitos Lithium Projects in Argentina, the Mt Paris Lithium Project in Tasmania, the Wee MacGregor Copper-Gold & Cobalt Project in Queensland, and the Erongo Graphite Project in Namibia.

The Company is focused on its Argentinian lithium projects - potentially a game-changing proposition given the project locations within the world renowned "Lithium Triangle" - host to the world's largest lithium resources. Argosy is targeting a fast-track development and production strategy through expedited technical works, testing and studies.

Argosy is committed to building a sustainable lithium production Company, highly leveraged to the forecast growth in the lithium-ion battery sector.

#### Appendix 1: AGY's Argentina Project Location Map





Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## Appendix 3B

#### New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

ARGOSY MINERALS LIMITED

ABN

27 073 391 189

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

Class of +securities issued or to be issued

Fully Paid Ordinary Shares

100,000,000

- 2 Number of +securities issued or to be issued (if known) or maximum number which may be issued
- Principal terms of the 3 if options, +securities (e.g. exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Fully Paid

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes
	<ul> <li>If the additional *securities do not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	
5	Issue price or consideration	\$0.03 per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Capital raising for development and exploration activities and working capital.
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the <sup>+</sup> securities the	Yes
	<i>subject of this Appendix 3B,</i> and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	31 May 2016
6с	Number of +securities issued without security holder approval under rule 7.1	35,524,922
6d	Number of +securities issued with security holder approval under rule 7.1A	64,475,078
бе	Number of <sup>+</sup> securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A

<sup>+</sup> See chapter 19 for defined terms.

- 6f Number of *+*securities issued under an exception in rule 7.2
- If +securities issued under rule 6g 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.
- If +securities were issued under 6h rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements
- +Issue dates 7 Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

- 8 Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)
- Number and +class of all 9 +securities not quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
12,500,000	Options exercisable at \$0.09 and

+Class

Shares

Ordinary Fully Paid

expiring 13/06/2017

Dividend policy (in the case of 10 trust, distribution policy) on th increased capital (interests)

f a	N/A	
he		

#### Part 2 - Pro rata issue

Yes – Issue price was \$0.03 each Date of issue: 20 October 2016 15 Day VWAP before issue date: \$0.025 75% of 15 Day VWAP: \$0.019 Source: Commsec

N/A

Rule 7.1 61,187,696 Rule7.1A Total 61,187,696

20 October 2016

Number

744,750,788

0		

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

11       Is security holder approval required?       N/A         12       Is the issue renounceable or non-renounceable?			
renounceable?         13       Ratio in which the *securities         14       *Class of *securities to which the offer relates         15       *Record date to determine entitlements         16       Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?         17       Policy for deciding entitlements in relation to fractions         18       Names of countries in which the entity has security holders who will not be sent new offer documents         Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.         19       Closing date for receipt of acceptances or renunciations         20       Names of any underwriting fee or commission         21       Amount of any underwriting fee or commission payable to the broker to the issue         23       Fee or commission payable to the payable to brokers who lodge acceptances or renunciations on	11	, , ,	7/A
will be offered         14       *Class of *securities to which the offer relates         15       *Record date to determine entitlements         16       Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?         17       Policy for deciding entitlements in relation to fractions         18       Names of countries in which the entity has security holders who will not be sent new offer documents         Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.         19       Closing date for receipt of acceptances or renunciations         20       Names of any underwriters         21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on	12		
offer relates         15       *Record date to determine entitlements         16       Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?         17       Policy for deciding entitlements in relation to fractions         18       Names of countries in which the entity has security holders who will not be sent new offer documents         Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.         19       Closing date for receipt of acceptances or renunciations         20       Names of any underwriters         21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on	13		
entitlements         16       Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?         17       Policy for deciding entitlements in relation to fractions         18       Names of countries in which the entity has security holders who will not be sent new offer documents         Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.         19       Closing date for receipt of acceptances or renunciations         20       Names of any underwriting fee or commission payable to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on	14		
registers (or subregisters) be aggregated for calculating entitlements?         17       Policy for deciding entitlements in relation to fractions         18       Names of countries in which the entity has security holders who will not be sent new offer documents         Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.         19       Closing date for receipt of acceptances or renunciations         20       Names of any underwriters         21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on	15		
<ul> <li>in relation to fractions</li> <li>18 Names of countries in which the entity has security holders who will not be sent new offer documents</li> <li>Note: Security holders must be told how their entitlements are to be dealt with.</li> <li>Cross reference: rule 7.7.</li> <li>19 Closing date for receipt of acceptances or renunciations</li> <li>20 Names of any underwriters</li> <li>21 Amount of any underwriting fee or commission</li> <li>22 Names of any brokers to the issue</li> <li>23 Fee or commission payable to the broker to the issue</li> <li>24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on</li> </ul>	16	registers (or subregisters) be aggregated for calculating	
entity has security holders who will not be sent new offer documents         Note: Security holders must be told how their entitlements are to be dealt with.         Cross reference: rule 7.7.         19       Closing date for receipt of acceptances or renunciations         20       Names of any underwriters         21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on	17		
entitlements are to be dealt with.         Cross reference: rule 7.7.         19       Closing date for receipt of acceptances or renunciations         20       Names of any underwriters         21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on	18	entity has security holders who will not be sent new offer	
19       Closing date for receipt of acceptances or renunciations         20       Names of any underwriters         21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on		entitlements are to be dealt with.	
acceptances or renunciations         20       Names of any underwriters         21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on			
21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on	19	Ũ .	
or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on	20	Names of any underwriters	
or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on			
<ul> <li>issue</li> <li>23 Fee or commission payable to the broker to the issue</li> <li>24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on</li> </ul>	21		
24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on	22	-	
payable to brokers who lodge acceptances or renunciations on	23		
	24	payable to brokers who lodge acceptances or renunciations on	

<sup>+</sup> See chapter 19 for defined terms.

- 25 If the issue is contingent on security holders' approval, the date of the meeting
- 26 Date entitlement and acceptance form and offer documents will be sent to persons entitled
- 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- 28 Date rights trading will begin (if applicable)
- 29 Date rights trading will end (if applicable)
- 30 How do security holders sell their entitlements *in full* through a broker?
- 31 How do security holders sell *part* of their entitlements through a broker and accept for the balance?
- 32 How do security holders dispose of their entitlements (except by sale through a broker)?
- 33 <sup>+</sup>Issue date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of \*securities (*tick one*)
- (a) +Securities described in Part 1
  - All other <sup>+</sup>securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

(b)

<sup>+</sup> See chapter 19 for defined terms.

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional <sup>+</sup> securities

#### Entities that have ticked box 34(b)

- Number of *+*securities for which 38 <sup>+</sup>quotation is sought +Class of +securities for which 39 quotation is sought Do the <sup>+</sup>securities rank equally in 40 all respects from the <sup>+</sup>issue date with an existing <sup>+</sup>class of quoted +securities? If the additional \*securities do not rank equally, please state: • the date from which they do the extent to which they • participate for the next dividend, (in the case of a trust, distribution) or interest
  - payment
    the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

<sup>+</sup> See chapter 19 for defined terms.

Reason for request for quotation now
 Example: In the case of restricted securities, end of restriction period
 (if issued upon conversion of another +security, clearly identify that other +security)

Number and +class of

quoted

(including the +securities in clause

Number	+Class

#### Quotation agreement

<sup>+</sup>securities

38)

42

<sup>1</sup> <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.

all

on ASX

- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

<sup>+</sup> See chapter 19 for defined terms.

We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 20 October 2016 (Director and Company secretary)

Print name: Andrea Betti

== == == == ==

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

Rule 7.1 – Issues exceeding 15% of capital Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Add the following:		
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> <li><i>Note:</i></li> <li><i>Include only ordinary securities here – other classes of equity securities cannot be added</i></li> <li><i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li><i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	1,000,000 (App 3B issued 26/5/16 – approved 16/9/16) 26,666,668 (App 3B issued 26/5/16 – approved 16/9/16) 58,698,900 (App 3B issued 2/6/16 - approved 29/5/15) 130,297,905 (App 3B issued 12/8/16 - approved 29/5/15)	
period "A"	644,750,788	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"			
"B"	0.15		
	[Note: this value cannot be changed]		
<i>Multiply</i> "A" by 0.15	96,712,618		
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule		
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	35,524,922 (this App 3B)		
• Under an exception in rule 7.2			
Under rule 7.1A			
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>			
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>			
"C"	35,524,922		
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining		
"A" x 0.15	96,712,618		
Note: number must be same as shown in Step 2			
Subtract "C"	35,524,922		
Note: number must be same as shown in Step 3			
<i>Total</i> ["A" x 0.15] – "C"	61,187,696		
	[Note: this is the remaining placement capacity under rule 7.1]		

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

Rule 7.1A – Additional placement capacity for eligible entities			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
"A"	644,750,788		
Note: number must be same as shown in Step 1 of Part 1			
Step 2: Calculate 10% of "A"			
"D"	0.10		
	Note: this value cannot be changed		
<i>Multiply</i> "A" by 0.10	64,475,078		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used			
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	64,475,078 (this App 3B)		
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>			
"E"	64,475,078		

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	64,475,078	
Note: number must be same as shown in Step 2		
Subtract "E"	64,475,078	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	0	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.



20 October 2016

The Manager Companies Announcements Office Australian Securities Exchange

Dear Sir/Madam

In accordance with the requirements of ASX listing rule 3.10.5A the following information is provided in relation to the attached Appendix 3B:

The dilution to existing shareholders, as a result of the issue under Listing Rule 7.1A is 10.0%, dilution to existing shareholders as a result of the issue under Listing Rule 7.1 is 5.5% and the total dilution to existing shareholders as a result of the issue is 15.5%.

Details of the approximate percentage of the issued capital following the completion of the issue held by pre-issue shareholders and new shareholders are as follows:

Pre-issue shareholders who did not participate in the 7.1A issue	100.0%
Pre-issue shareholders who did participate in the 7.1A issue	0.0%
Participants in the 7.1A issue who were not previously shareholders	100.0%

The Company issued the shares for cash to assist with the advancement and progress of the Company's existing projects and working capital. The Company undertook the placement capital raising as any other method would have taken much longer and incurred significant additional costs.

No underwriting arrangements were in place for the issue and there were no capital raising fees in relation to the capital raised.

Yours faithfully,

OXILOTE

Andrea Betti Director Company Secretary